The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study.
List view / Grid view
renal cell carcinoma (RCC)
Filter the results
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending cabozantinib for some kidney cancer patients
12 January 2017 | By Niamh Marriott, Digital Editor
Everolimus (Afinitor, Novartis) is now recommended to be available on the NHS as a treatment option for some patients with advanced renal cell carcinoma...
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Ipsen announced that CHMP & EMA have provided a positive opinion for Cabometyx for the treatment of advanced renal cell carcinoma (RCC) in adults...
8 July 2016 | By Victoria White, Digital Content Producer
The S-TRAC study of Sutent versus placebo in the adjuvant setting met its primary endpoint of improving disease-free survival in renal cell carcinoma...